FDA Panel Endorses Class II Status for Surgical Mesh Instrumentation
This article was originally published in The Gray Sheet
Executive Summary
The Gastroenterology and Urology Devices Panel supported FDA’s proposal to up-classify surgical mesh instrumentation from class I to class II with special controls.
You may also be interested in...
FDA Moves Mesh Surgical Instrumentation Up To Class II In Final Order
The US agency has agreed with an earlier assessment by an advisory panel last year to up-classify surgical mesh instrumentation by issuing a Jan. 6 final order to move the instrumentation – used for women undergoing pelvic organ prolapse or female stress incontinence procedures – from class I to class II.
Making The Case For A Legislative Deal On Drug Pricing
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: